Jonilda Sulo

Dr. Jonilda Sulo

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2026 in PLOS Global Public Health
Verified
Journal Article
Open access
JSJonilda Sulo
Jonilda Sulo
KMKujtim Mersini
Kujtim Mersini
EKElona Kureta
Elona Kureta
IHIris Hatibi
Iris Hatibi
NCNajada Como
Najada Como
SBSilvia Bino
Silvia Bino
The COVID-19 pandemic has significantly affected Albania, with over 319959 cases and 3625 deaths by December 2023. Despite a national vaccination campaign initiated in January 2021, only 44.1% of the eligible population had completed the full vaccination regimen by late 2023. In this study, we aim to estimate the effectiveness of COVID-19 vaccines in preventing severe outcomes and in assessing association of prior SARS-CoV-2 infection among adults hospitalized with COVID-19 in Albania. A test-negative case-control study was conducted using SARI sentinel surveillance data from July 2022 to July 2023. The study included 1858 hospitalized SARI patients aged 18 and older, with 410 testing positive for SARS-CoV-2 (cases) and 1448 testing negative (controls). Vaccine effectiveness was calculated using logistic regression, adjusting for age, sex, comorbidities, and hospital stay duration. The overall adjusted vaccine effectiveness (VE) for preventing hospitalization was 30.1% for those fully vaccinated with two doses and 31.4% for those with a booster. VE against severe outcomes was 30.6%, increasing to 37.8% after a booster. The highest VE was observed in patients aged 80 and above, reaching 52.5% after a booster. Prior SARS-CoV-2 infection combined with vaccination was associated with higher VE to 76.2%. However, many VE estimates had wide confidence intervals overlapping zero, indicating considerable uncertainty and lack of statistical significance in some subgroup results. This study provides real-world evidence of an association between COVID-19 vaccination, particularly with booster doses, and lower odds of severe outcomes. VE was highest among elderly patients and in those with prior SARS-CoV-2 infection, emphasizing the importance of booster campaigns in vulnerable populations.

10 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KMKujtim Mersini
Kujtim Mersini
AVAdela Vasili
Adela Vasili
JSJonilda Sulo
Jonilda Sulo
EKElona Kureta
Elona Kureta
ASArtan Simaku
Artan Simaku
SBSILVIA BINO
SILVIA BINO
One Health surveillance requires that information from one sector triggers assessment and action in another. This descriptive case study examines how Albania’s Integrated Surveillance Information System (SISI) operationalised cross-sectoral event-based surveillance (EBS) and what limited routine interoperability, using governance documents, the EBS register of April 2020 to August 2026 and staff surveys. The register held 399 signals, 93 of them animal-health or suspected zoonotic events. Of 363 completed verifications, 255 (70.2%) were substantiated and 41 had a recorded escalation to case notification or outbreak investigation. Veterinary services initiated 26 signals, 20 of 23 with dates registered within two days. After one veterinary brucellosis signal, contact investigation found two confirmed human infections within six days, and avian influenza A(H5N1) signals led to testing of 60 exposed persons, all negative. Human anthrax and brucellosis events were signalled to veterinary services, with an animal source identified in two. Integration was operational at the event level, through reciprocal-signalling rules, shared event records and defined field responsibilities. Routine data remained unjoined, since the veterinary system was unlinked, animal-side actions were unevenly documented, community participation declined and cybersecurity constrained interfaces. Event-level integration can offer a transferable starting point where routine data systems cannot yet be joined.